Literature DB >> 27120000

Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.

C Zecca1, G C Riccitelli1,2, G Disanto1, A Singh3, G A Digesu3,4, L Panicari1, F Puccini5, M Mattioli5, A Tubaro5, C Gobbi1.   

Abstract

BACKGROUND AND
PURPOSE: Lower urinary tract symptoms (LUTS) including frequent urination, nocturia and urge urinary incontinence negatively impact quality of life. This project aimed at characterizing the prevalence and severity of urinary incontinence in multiple sclerosis (MS) patients and its association with demographic and clinical features.
METHODS: In all, 403 consecutive clinically stable MS patients answered the International Consultation on Incontinence Questionnaire (ICIQ) and the Patient Perception of Bladder Condition (PPBC) questionnaire. Demographic and clinical parameters including the Expanded Disability Status Scale (EDSS) were collected. Statistical analyses were performed using univariate and multivariate linear regression models.
RESULTS: Females represented 72%, relapsing-remitting patients 82%. The mean (SD) disease duration and EDSS were 11.8 (8.6) years and 3.1 (1.9) respectively. Approximately 35% of patients reported urine incontinence. ICIQ scores were positively associated with EDSS, female gender, presence of LUTS therapies and absence of disease modifying treatments (P < 0.001). PPBC scores were positively associated with EDSS and the presence of LUTS therapies (P < 0.001). DISCUSSION: Urinary incontinence is frequent in MS, prevailing in more disabled and female patients. Currently available LUTS therapies appear insufficient in the treatment of this symptom. The negative impact of urinary incontinence on quality of life is high and requires more attention in clinical management and research.
© 2016 EAN.

Entities:  

Keywords:  lower urinary tract symptoms; multiple sclerosis; prevalence; quality of life; urinary incontinence

Mesh:

Year:  2016        PMID: 27120000     DOI: 10.1111/ene.13010

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.

Authors:  Giorgia Teresa Maniscalco; R Aponte; D Bruzzese; G Guarcello; V Manzo; M Napolitano; O Moreggia; F Chiariello; C Florio
Journal:  Neurol Sci       Date:  2017-10-19       Impact factor: 3.307

2.  What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT.

Authors:  Rafiyah Khan; Alan Uren; Luke Canham; David Cottrell; Marcus J Drake; Nikki Cotterill
Journal:  Mult Scler Int       Date:  2018-10-18

3.  Lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis.

Authors:  André Luiz Farinhas Tomé; Eduardo P Miranda; José de Bessa Júnior; Carlos Alberto Bezerra; Antônio Carlos Lima Pompeo; Sidney Glina; Cristiano Mendes Gomes
Journal:  Clinics (Sao Paulo)       Date:  2019-03-14       Impact factor: 2.365

4.  Bladder Dysfunction in Iranian Patients with Multiple Sclerosis.

Authors:  Mohaddeseh Azadvari; Seyede Zahra Emami Razavi; Masumeh Shahrooei; Abdorreza Naser Moghadasi; Amirreza Azimi; Hamid Reza Farhadi-Shabestari
Journal:  J Multidiscip Healthc       Date:  2020-04-02

Review 5.  Oxidative Stress: A Putative Link Between Lower Urinary Tract Symptoms and Aging and Major Chronic Diseases.

Authors:  Zhenqun Xu; Rania A Elrashidy; Bo Li; Guiming Liu
Journal:  Front Med (Lausanne)       Date:  2022-03-10

6.  Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.

Authors:  Hawra B Al Dandan; Susan Coote; Doreen McClurg
Journal:  Int J MS Care       Date:  2020 Mar-Apr

7.  Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Authors:  Rivka Green; Gary Cutter; Michael Friendly; Ilya Kister
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-05

8.  Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.

Authors:  Mark Tullman; Emmanuel Chartier-Kastler; Alfred Kohan; Veronique Keppenne; Benjamin M Brucker; Blair Egerdie; Meryl Mandle; Jean Paul Nicandro; Brenda Jenkins; Pierre Denys
Journal:  Neurology       Date:  2018-07-20       Impact factor: 9.910

9.  The use of brain stimulation in the rehabilitation of walking disability in patients with multiple sclerosis: A randomized double-blind clinical trial study.

Authors:  Shahram Oveisgharan; Zahra Karimi; Siamak Abdi; Hajir Sikaroodi
Journal:  Iran J Neurol       Date:  2019-04-04

10.  Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches.

Authors:  Anna Onisiforou; George M Spyrou
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.